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Aims
Prognostic models are statistical models that predict the
risk of a future clinical outcome for individuals, and
they are increasingly being developed using existing data
from clinical trials. In this presentation we consider the
challenges of this approach.
Methods
Using data from two clinical trials in advanced stage
pancreatic cancer, a prognostic model was developed
using Royston-Parmar (R-P) flexible parametric survival
models. R-P models use restricted cubic splines to
model the baseline hazard function for time-to-event
data and thereby allows absolute risk to be predicted for
individuals. This contrasts the Cox regression approach
which does not explicitly model the baseline hazard
function.
Results
We identified 6 key issues when using the trials’ data to
develop the prognostic model. These included dealing
with multiple trials, handling multiple treatment groups
with potentially different baseline hazard functions, and
suitably using the data for model validation.
Informed judgement is needed to tackle these issues,
and the baseline hazard function is pivotal to this. R-P
models allow the baseline hazard to be displayed for all
trials and all treatment groups. This aids decisions
about whether to combine trials and treatment groups
in the model development, and enables internal valida-
tion of predicted survival probabilities compared to
observed probabilities from Kaplan-Meier plots.
Conclusion
Clinical trials data is a rich source of existing data for
prognostic model development, but it also provides
many challenges. By modelling the baseline hazard,
researchers can gain insight into how to tackle these
issues.
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